Nuvectis Pharma (NASDAQ:NVCT) Announces Quarterly Earnings Results, Misses Estimates By $0.78 EPS

Nuvectis Pharma (NASDAQ:NVCT) issued its quarterly earnings data on Wednesday. The company reported ($1.02) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.78), Zacks reports.

Here are the key takeaways from Nuvectis Pharma’s conference call:

• NXP100 has moved into commercial-stage development in China: Ciprocopan was approved for treatment-naive PNH patients after a Phase III study that management said outperformed Soliris on the primary and key secondary endpoints. A second Chinese PNH approval, for previously treated patients, is expected in Q1 2027.
• The U.S. PNH pathway remains uncertain and may require new trials. FDA discussions are ongoing; although management said the agency’s questions about the China studies were addressed, it realistically expects at least one U.S. study and is preparing for possibilities ranging from one to two trials.
• NXP100 could have opportunities beyond PNH, though evidence is still developing. Its China Phase II IgA nephropathy results included a 57% proteinuria reduction and an improvement in eGFR; a larger Phase III readout is expected around April or May 2027, and the company plans to pursue additional U.S. indications.
• NXP200 showed encouraging early activity in glioma. Management cited a 40% response rate in the 20-patient high-grade glioma cohort, including three complete responses, and plans a U.S. IND by year-end with a Phase I-B study targeted for early 2027. Further China data across other tumor types is expected in the next few months.
• Cash provides runway into the second half of 2029. Nuvectis ended the quarter with about $140 million, following a $150 million follow-on offering and roughly $37 million raised through its ATM; management says the funds should support multiple pipeline milestones.

Nuvectis Pharma Stock Down 4.5%

NASDAQ NVCT opened at $18.47 on Thursday. The firm’s fifty day simple moving average is $21.12 and its two-hundred day simple moving average is $14.77. Nuvectis Pharma has a 12-month low of $5.55 and a 12-month high of $29.27.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $39.00 price target on shares of Nuvectis Pharma in a report on Thursday, September 24th. Lucid Cap Mkts upgraded Nuvectis Pharma to a “strong-buy” rating in a research note on Tuesday, September 1st. Weiss Ratings raised Nuvectis Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, September 21st. Loop Capital set a $40.00 price objective on Nuvectis Pharma in a research report on Tuesday, September 1st. Finally, Cantor Fitzgerald began coverage on Nuvectis Pharma in a research note on Monday, August 24th. They issued an “overweight” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Nuvectis Pharma presently has a consensus rating of “Moderate Buy” and an average price target of $36.25.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer, with an emphasis on cancers that have limited therapeutic options. The company is headquartered in Fort Lee, New Jersey, and its common stock trades on the Nasdaq Capital Market under the symbol NVCT.

Nuvectis Pharma’s lead product candidate is NXP800, an orally administered small-molecule inhibitor of heat shock protein 90 (HSP90). The company is evaluating NXP800 in clinical studies for certain advanced solid tumors, including platinum-resistant ovarian cancer and cholangiocarcinoma.